secwatch.observer — SEC 8-K summary
======================================

Issuer:     Mineralys Therapeutics, Inc. (MLYS)
CIK:        0001933414
Form:       8-K
Filed at:   2024-08-13T23:59:59+00:00
Accession:  0001933414-24-000038
Event type: earnings
Sentiment:  neutral
Materiality: 0.55
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Mineralys reports Q2 net loss $41M; Advance-HTN trial ~90% enrolled, on track for Q1 2025 data
--------------------------------------------------------------------------------

- Net loss of $41.0M for Q2 2024 vs $12.1M in Q2 2023; cash and investments of $311.1M as of June 30, 2024.
- Advance-HTN pivotal trial ~90% enrolled; topline data expected Q1 2025 after FDA alignment on primary endpoint.
- Launch-HTN Phase 3 enrollment ahead of schedule; topline data on track for 2H 2025.
- Explore-CKD Phase 2 trial enrollment ramping; topline data expected 1H 2025.
- Cash runway into 2026 covers planned clinical studies and corporate operations.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000038/0001933414-24-000038-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1933414/000193341424000038/mlys-20240813.htm
  HTML page:      https://secwatch.observer/filing/0001933414-24-000038

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer